INHBA is a prognostic predictor for patients with colon adenocarcinoma

Xueying Li¹, Weiming Yu², Chao Liang², Yuan Xu², Miaozun Zhang², Xiaoyun Ding¹ and Xianlei Cai²*

Abstract

Background: Colon adenocarcinoma (COAD) is one of the most lethal cancers. It is particularly important to accurately predict prognosis and to provide individualized treatment. Several lines of evidence suggest that genetic factors and clinicopathological characteristics are related to cancer onset and progression. The aim of this study was to identify potential prognostic genes and to develop a nomogram to predict survival and recurrence of COAD.

Methods: To identify potential prognostic genes in COAD, microarray datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were obtained from GEO2R. Venn diagram was drawn to select those genes that were overexpressed in all datasets, and survival analyses were performed to determine the prognostic values of the selected genes. New nomograms were developed based on the genes that were significantly associated with prognosis. Clinicopathological data were obtained from The Cancer Genome Atlas (TCGA). Finally, the new nomograms were compared head-to-head comparison with the TNM nomogram.

Results: From GSE21510, GSE110223, GSE113513 and GSE110224, a total of 834, 218, 236 and 613 overexpressed DEGs were screened out, respectively. The Venn diagram revealed that 12 genes appeared in all four profiles. After survival analyses, only INHBA expression was associated with both overall survival (OS) and disease-free survival (DFS). Multivariate analyses revealed that age, pathological N and pathological M were significant independent risk factors for OS. Age, pathological N, pathological M and INHBA were significant independent risk factors for DFS. Two prediction models predicted the probability of 3-year survival and 5-year survival for OS and DFS, respectively. The concordance indexes were 0.785 for 3-year overall survival, 0.759 for 5-year overall survival, 0.789 for 3-year disease-free survival and 0.757 for 5-year disease-free survival. The head-to-head comparison according to time-dependent ROC curves indicated that the new models had higher predictive accuracy. Decision curve analyses (DCA) indicated that the clinical value of the new models were higher than TNM models for predicting disease-free survival.

Conclusion: The combination of INHBA expression with a clinical nomogram improves prognostic power in colon adenocarcinoma, especially for predicting recurrence.

Keywords: Colon adenocarcinoma, Bioinformatics analysis, INHBA, Nomogram
Background
Colorectal cancer (CRC) ranks second among the world’s top ten cancers [1]. In 2018, more than 1.8 million new CRC cases were diagnosed and 880,000 cancer-related deaths occurred worldwide [2]. In China, the incidence and mortality of CRC rank fifth and fourth, respectively [3]. Colon adenocarcinoma is one of the most common types of CRC [4] and has become more prevalent in recent years [5]. Comprehensive treatment based on multidisciplinary discussion has become the trend of CRC treatment. Despite the fact that surgery combined with chemotherapy, as well as targeted therapy and immunotherapy have improved prognosis, the overall efficacy, especially long-term and high-quality survival remain unsatisfactory.

The prognosis of colon adenocarcinoma primarily depends on the extent of disease. Nevertheless, various prognostic factors have been observed in addition to disease extent. American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) stage. There prognostic factors include age, gender and gene expression [6, 7]. With the rapid development of gene sequencing technology, GEO and TCGA have been playing increasing important roles in bioinformatics analysis [8, 9]. These databases provide sequencing data for discovery of new functional genes and for analyzing the effect of these genes on prognosis. These analyses require a new method, combining clinical characteristics and gene information; a nomogram is a good tool for this purpose.

Therefore, the aim of this study was to identify prognostic genes using comprehensive bioinformatic analysis and to develop a nomogram to predict the overall survival and disease-free survival of patients with COAD based on GEO and TCGA databases.

Methods
Microarray data
In the discovery step, we identified datasets that compared mRNA expression in CRC tissue with that of normal tissue. Gene expression profiles of GSE21510 (with 148 samples), GSE110223 (with 26 samples), GSE113513 (with 28 samples) and GSE110224 (with 34 samples) were obtained from the National Center for Biotechnology Information (NCBI) GEO database (https://www.ncbi.nlm.nih.gov/geo/). GSE21510 and GSE11024 datasets were based on the GPL570 platform, while GSE110223 was based on the GPL96 platform and GSE113513 was based on the GPL15207 platform.

Screening for integrated differentially expressed genes (DEGs)
GEO2R, the tool provided by the GEO database that depends on R package ‘limma’ was used to identify DEGs in each dataset. Adjusted \( p \) values \(< 0.05\) and \( \log_{2}\text{FC} > 1\) were set as cut-off criteria for screening out the overexpressed DEGs. The list of significantly up-regulated genes was exported separately.

A Venn diagram containing four lists of up-regulated genes was drawn online (http://bioinformatics.psb.ugent.be/webtools/Venn/) to identify those genes that were overexpressed in all datasets. All expression levels of selected genes were verified in TCGA (http://ualcan.path.uab.edu/) [10]. We drew a heatmap describing levels of potential hub gene expression.

Kaplan - Meier survival analysis
The prognostic values of selected genes were analyzed. Gene expression profiling and interactive analyses (GEPIA) [11] were used for survival analyses (http://gepia.cancer-pku.cn/). The GEPIA contains 9736 tumors and 8587 normal samples from TCGA and GTEx. Kaplan - Meier plots of OS and DFS were drawn and hazard ratios (HRs) were calculated for each selected gene individually. Log rank \( p \)-values were presented, and those genes significantly associated with prognosis were entered into the next stage of model building.

Clinical and bioinformatic information
TCGA was accessed on May 5, 2019, and a total of 459 COAD patient clinical data with tumors’ RNA expression data were collected (https://tcga-data.nci.nih.gov/). Clinical parameters included gender, age, pathologic T stage, pathologic N stage, pathologic M stage, vital status, recurrent status and follow-up period (days). Considering the influence of surgical factors, we excluded those cases whose follow-up time were less than 30 days. Median RNA expression value was regarded as the cut-off to divide patients into high or low expression groups.

Development of risk prediction model
According to TCGA data, we developed a nomogram combing gene expression with clinical information (new model) for prediction of survival and recurrence at 3 years and 5 years in individual COAD patients. Another nomogram based on pathologic TNM stage (TNM model) was developed for head-to-head comparison with the first comprehensive model.

Statistical analysis
We used the Cox proportional hazard regression model to estimate hazard ratio (and its 95% confidence interval (CI)) for each potential risk factor. Inclusion and exclusion criteria of type I error \(= 0.1\) were set in the stepwise multivariate Cox regression analysis.

The discrimination reflects the ability of a model to distinguish events and non-events correctly, and these were validated using C-statistics. The Concordance index (C-index) is analogous to the area under the
receiver operating characteristic (ROC) curve. The predictive capacity of models was summarized using time-dependent ROC curves [12, 13]. The calibration refers to the closeness between the predicted probabilities and the actual outcomes, and this was validated using calibration plots [14]. To test the clinical value of the predictive new model, we generated a decision curve analysis graph to visualize the potential net benefit between two models at each threshold probability [15, 16].

To calculate sample size, we set expected sensitivity as 70%, expected specificity as 90%, permissible error of sensitivity and specificity both as 5%, and alpha (two-sided) as 0.05 [17, 18]. After calculation, the expected sample size was 323. This demonstrated that number of TCGA patients was sufficient for this study.

A two-sided p-value of <0.05 was considered statistically significant. All statistical analyses were conducted using R software for Windows, version 3.6.1.

Results

Identification of DEGs in COAD

We downloaded four COAD gene expression profiles (GSE21510, GSE110223, GSE113513 and GSE110224) from the GEO database and screened out 834, 218, 236 and 613 overexpressed DEGs respectively using GEO2R. A Venn diagram was generated (Fig. 1) and 12 genes (CD44, RFC3, CDK1, NPM1, MAD2L1, MTHFD2, OSBPL3, CSE1L, INHBA, ATAD2, PMAIP1 and PPAT) that were overexpressed in the four profiles were discovered. The 12 selected genes were verified in TCGA and charted on a heat map (Fig. 2).

Survival analysis

To further explore the survival values of the 12 selected genes, we drew Kaplan - Meier curves of OS and DFS according to gene expression. Only INHBA exhibited statistical significance in both OS and DFS curves (Fig. 3, log-rank p = 0.045 and 0.040, respectively). High levels of INHBA expression were associated with poor prognosis, while the other eleven genes did not present prognostic prediction values for OS or DFS (Supplementary Figure 1 and Supplementary Figure 2). Therefore, only INHBA was entered into the subsequent stage of model building.

Baseline patient characteristics in TCGA

Clinicopathological data were integrated with INHBA expression levels. Median of INHBA expression was used to divide patients into high-INHBA groups and low- INHBA groups. Patients who had a follow-up time less than 30 days or had no clinical overall survival or disease-free survival information were excluded. Finally, data on 420 COAD patients for OS and data on 388 COAD patients for DFS were obtained. Detailed baseline characteristics are summarized in Table 1.

Risk factors for overall survival and disease-free survival

In the univariate Cox analysis, age, pathological T, pathological N, pathological M and INHBA were all associated with overall survival and disease-free survival (Table 2). By contrast, gender did not have a significant effect. The significant risk factors determined in the univariate analysis were used in multivariate Cox analysis. Finally, age, pathological N and pathological M emerged as significant independent risk factors for OS, while age, pathological N, pathological M and INHBA were significant independent factors for DFS (Table 2).
Based on these results, we developed two prediction models and generated graphical nomograms predicting the probability of 3-year survival and 5-year survival for OS and DFS, respectively (Figs. 4 and 5). INHBA was also included in the nomogram of OS according to the exclusion criterion of 0.1. The predictive accuracy of the nomograms calculated by AUC were 0.785 for 3-year overall survival, 0.759 for 5-year overall survival, 0.789 for 3-year disease-free survival and 0.757 for 5-year disease-free survival (Fig. 6). The calibration plots revealed good agreement between the observed outcome and predicted probability (Supplementary Figure 3).

We also developed two prediction models based on TNM status (Supplementary Figure 4 and Supplementary Figure 5). The C-indexes were 0.748 for 3-year overall survival, 0.695 for 5-year overall survival, 0.688 for 3-year disease-free survival and 0.664 for 5-year disease-free survival. The time-dependent ROC curves also demonstrated that the predictive accuracy of new models were significantly higher than those of the TNM models (Fig. 7). The clinical value of new models were also higher than those of the TNM models for predicting disease-free survival, but were similar with that of TNM models for predicting overall survival (Fig. 8). The new models had a higher net benefit for predicting DFS than the TNM models for almost all threshold probabilities.

**Discussion**

Colon adenocarcinoma is a heterogeneous malignancy with high recurrence probability and dismal prognosis. Currently, effective therapeutic strategies against recurrence and metastatic COAD remain rare. Therefore, it is important to develop a new prognostic tool to identify patients at high risk of recurrence who require more attention and treatment. It is also imperative to seek a promising therapeutic target for anti-tumor drug development to improve survival of advanced COAD.

In this study, we discovered 12 DEGs that were over-expressed in four mRNA arrays downloaded from the GEO dataset and we verified them in TCGA. According to survival analysis, INHBA was associated with both overall survival and disease-free survival. Univariate and multivariate Cox analysis were performed to process COAD clinicopathological information downloaded from TCGA. Age, pathological N and pathological M were significant independent factors for OS and DFS, while INHBA was an independent risk factor for DFS.
Moreover, new graphical nomograms combining INHBA expression with clinicopathological data were generated to predict OS and DFS. For example, a 60-year-old patient (51 points) with AJCC stage TxN2 (74 points) M0 (0 points) and INHBA high expression (38 points) had a total score of 163 points. The predicted 3-year disease free survival would be approximately 37% and the predicted 5-year disease free survival would be approximately 26%. These estimates could be used in patient counseling and decision making. Finally, we developed two prediction models based on TNM status to compared with the new models. The C-index and the time-dependent ROC curves all revealed the new models had better discrimination than the TNM models. The DCA graph also indicated higher clinical value of the new model for predicting disease-free survival than the TNM model.

The mechanism of INHBA gene expression affecting outcomes in COAD remains to be fully investigated. Inhibin βA (INHBA), is a member of the transforming growth factor-β superfamily. It is involved in multiple biological processes such as cell cycle, proliferation, migration, and invasion. The exact role of INHBA in COAD pathogenesis and its potential as a therapeutic target warrants further investigation.

### Table 2

| Factors | Subgroup | OS set (n = 420) | DFS set (n = 388) |
|---------|----------|-----------------|------------------|
|         | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|         | HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p |
| Age     | <65  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|         | 65–74 | 0.99 | 0.55–1.75 | 0.960 | 1.29 | 0.72–2.32 | 0.393 | 0.47 | 0.27–0.81 | 0.007 | 0.50 | 0.28–0.88 | 0.016 |
|         | ≥75   | 1.86 | 1.13–3.09 | 0.001 | 2.28 | 1.36–3.83 | 0.001 | 0.90 | 0.60–1.57 | 0.897 | 1.23 | 0.75–2.02 | 0.421 |
| Gender  | Male  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|         | Female | 1.18 | 0.55–1.31 | 0.466 | 0.75 | 0.49–1.16 | 0.199 | 0.75 | 0.49–1.16 | 0.199 |
| pT      | T1    | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|         | T2    | 1.62 | 0.06–5.96 | 0.676 | 0.46 | 0.05–4.48 | 0.504 | 1.11 | 0.13–9.22 | 0.927 | 1.12 | 0.13–9.50 | 0.917 |
|         | T3    | 2.28 | 0.32–16.49 | 0.414 | 1.16 | 0.16–8.61 | 0.886 | 2.79 | 0.39–20.16 | 0.309 | 1.95 | 0.26–14.50 | 0.514 |
|         | T4    | 8.10 | 1.08–60.79 | 0.042 | 3.25 | 0.42–25.42 | 0.262 | 7.68 | 1.01–58.58 | 0.049 | 4.77 | 0.60–37.82 | 0.139 |
| pN      | N0    | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|         | N1    | 1.72 | 0.98–2.99 | 0.056 | 1.25 | 0.68–2.29 | 0.467 | 1.41 | 0.83–2.40 | 0.206 | 0.78 | 0.44–1.40 | 0.406 |
|         | N2    | 4.38 | 2.65–7.21 | 0.000 | 2.46 | 1.36–4.46 | 0.003 | 4.22 | 2.55–6.96 | 0.000 | 2.40 | 1.36–4.24 | 0.002 |
| pM      | M0    | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|         | M1    | 4.08 | 2.55–6.53 | 0.000 | 2.25 | 1.29–3.91 | 0.004 | 4.69 | 2.85–7.70 | 0.000 | 3.66 | 2.06–6.53 | 0.000 |
| INHBA   | Low   | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|         | High  | 1.65 | 1.07–2.55 | 0.024 | 1.44 | 0.93–2.25 | 0.100 | 1.94 | 1.27–2.97 | 0.002 | 1.71 | 1.10–2.65 | 0.017 |

**Fig. 4** Nomogram to predict 3-year and 5-year overall survival. Each risk factor corresponded to a point by drawing a line straight upward to the points axis. The sum of the points located on the total points axis represented the probability of 3-year and 5-year overall survival by drawing a line straight down to the survival axis.
Fig. 5 Nomogram to predict 3-year and 5-year disease free survival. Each risk factor corresponded to a point by drawing a line straight upward to the points axis. The sum of the points located on the total points axis represented the probability of 3-year and 5-year disease free survival by drawing a line straight down to the survival axis.

Fig. 6 The ROC curves represented the discrimination of the models measured by the C-index: a. for 3-year overall survival; b. for 5-year overall survival; c. for 3-year disease free survival; d. for 5-year disease free survival.
growth factor-β (TGF-β) superfamily, that has been found to participate in invasion and metastasis in various malignant tumors [6, 19–23]. Chen et al. study found that INHBA promotes gastric cancer migration and invasion via the TGF-β signaling pathway [21]. This pathway is involved in many processes of organismal and embryonic development, including cell growth, differentiation, apoptosis, homeostasis and others. In addition to activating the SMAD pathway, the type II receptor of TGF-β activates the non-classical signaling pathway PI3K/AKT, thereby promoting invasion and metastasis [24]. Previous studies [25, 26] have found that oncogenes

![Fig. 7](image_url) The time dependent ROC curves comparing the new models with the TNM models: a. Overall survival; b. Disease free survival

![Fig. 8](image_url) The DCA curves represented the clinical value of the models when comparing the new models with the TNM models: a. 3-year overall survival; b. 5-year overall survival; c. 3-year disease-free survival; d. 5-year disease-free survival
promote the Warburg effect [27] of cancer cells via the PI3K/AKT signaling pathway and affect glycometabolic reprogramming.

The TNM staging system is the foundation of prognosis prediction in colorectal cancer. Nevertheless, the prognostic power of TNM stage could be enhanced by a number of clinical, genetic and patient characteristics [28–30]. There have been several nomograms developed that predict survival for colorectal cancer. The first clinical nomogram was reported by Massacesi et al. [31]. They used CEA, number of sites, performance status (PS) and response to first-line chemotherapy to develop a nomogram for predicting long-term survival beyond 2 years in advanced colorectal cancer. Some nomograms studies focused on CRC patients with liver metastases. Tez, et al. reported an initial US nomogram in 2008 for predicting 96-month disease-specific survival for patients with stage IV CRC after liver resection [32]. That nomogram included ten risk factors and achieved a C-index of 0.61. Kanemitsu, et al. developed a similar prognostic model for predicting death after liver resection in individuals with hepatic metastases with a C-index of 0.66 [33]. Takakura, et al. study externally validated these two models using clinical data from Hiroshima University Hospital between 1995 and 2006, and found high predictive accuracy for both nomograms [34]. Reddy, et al. also used a prognostic nomogram to evaluate peri-operative chemotherapy after resection of colorectal liver metastases [35]. Fendler, et al. focused on patients after selective internal radiation therapy of hepatic metastases [36]. Elias, et al. regarded tumor load (number of liver metastasis and peritoneal carcinomatosis index) and procedure (liver resection or/and hyperthermic intraperitoneal chemotherapy) as variables to generate a nomogram to estimate patient survival before undergoing optimal surgery [37]. This nomogram must be validated in other tertiary centers. Valentini, et al. generated brilliant nomograms based on five European randomized clinical trials for local recurrence, distant metastases and OS for patients with locally advanced rectal cancer [38]. Their study had a large sample size (2795 cases) with external validation, and the results were accurate and reliable. There are other models [39, 40] for predicting survival and recurrence in patients with rectal cancer. Nevertheless, there are no such prediction models combining genetic information with clinical data.

The present study has several advantages. First, to our knowledge, this is the first nomogram combining genetic information with clinical data for predicting survival and recurrence in patients with COAD. The tool is user-friendly for counseling patients even at the bedside. Second, we performed a head-to-head comparison with a TNM nomogram based on TCGA clinical data. The results suggest that combined consideration of genetic and clinical information could better predict prognosis. Third, we adopted a high technical standard in statistical methodology. Innovative analytical techniques were employed, including time-dependent ROC and DCA. The time-dependent ROC curve is a popular method for displaying AUC over time. DCA curves are widely used to measure clinical utility of a specific model by comprehensively considering the relative value of benefits and harms associated with the prediction model in addition to sensitivity and specificity. These two methods could be interpreted simply and graphically and compared to the values of the two models better, thereby improving the accuracy of the results.

The current study also has some limitations. Despite a series of bioinformatics, we found potential prognostic genes. Nevertheless, this has not been verified using laboratory experiments. The generation of prediction models depended on a retrospective data from TCGA. The types of clinical data are limited and do not include other potential risk factors such as blood test results and undergoing chronic disease. Finally, this nomogram was not validated with external data as limited by conditions.

**Conclusion**

The combination of the INHBA expression signature with a clinical nomogram improves the prognostic capability in colon adenocarcinoma, especially for predicting recurrence. Further prospective studies are recommended to validate the models externally. The mechanism of INHBA in COAD need to be fully investigated.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-06743-2.
DEGs: Differentially expressed genes; DFS: Disease-free survival; GEO: Gene Expression Omnibus; GEPIA: Gene expression profiling and interactive analyses; INHBA: Inhibin βA; NCBI: National Center for Biotechnology Information; OS: Overall survival; ROC: Receiver operating characteristic; TCGA: The Cancer Genome Atlas; TNM: Tumor Node Metastasis

Acknowledgements
We appreciate the Gene Expression Omnibus database and The Cancer Genome Atlas for the open data.

Authors’ contributions
XC and XL conceived and designed the study; XL acquired and analyzed the data; XL, WY and CL interpreted the data and drafted the manuscript; YX, MZ and XD modified the manuscript. All authors approved the final version to be published.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Gastroenterology, Ningbo First Hospital, Ningbo, China. 2Department of Gastrointestinal Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, China.

Received: 30 December 2019 Accepted: 12 March 2020

Published online: 15 April 2020

References
1. Fitzmaurice C, Akinenyiiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alishan U, Alvis-Guzman N, Amini E, Anderson BO, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA oncology. 2018;4(11):1553–68.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C, Yang Z, He J. Cancer incidence and mortality in China in 2013: An analysis based on urbanization level. Chin J Cancer Res. 2017;29(1):1–10.
4. Zhang Z, Qian W, Wang S, Ji D, Wang Q, Li J, Peng W, Gu J, Hu T, Ji B, et al. Analysis of IncRNA-associated ceRNA network reveals potential IncRNA biomarkers in human Colon adenocarcinoma. Cell Physiol Biochem. 2018;49(5):1778–91.
5. Jiang H, Du J, Gu J, Jin L, Pu Y, Fei B. A 65gene signature for prognostic prediction in colon adenocarcinoma. Int J Mol Med. 2018;41(4):2021–7.
6. Okano K, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, Konno M, Kawamoto K, Haraguchi N, Takemasa I, et al. Significance of INHBA expression in human colorectal cancer. Oncol Rep. 2013;30(6):2903–8.
7. Eom BW, Ryu KW, Nam BH, Park Y, Lee HJ, Kim MC, Cho GS, Kim CY, Ryu SW, Shin DW, et al. Survival nomogram for curatively resected Korean gastric cancer patients: multicenter retrospective analysis with external validation. PLoS One. 2015;10(2):e0119671.
8. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashovsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D991–5.
9. Rau A, Flipter M, Rui H, Auer PL. Exploring drivers of gene expression in the Cancer Genome Atlas. Bioinformatics. 2019;35(1):162–8.
10. Chandrashekar DS, Bashel B, Balasubramanaya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(9):549–58.
11. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z, GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102.
12. Zheng Y, Heagerty PJ. Semiparametric estimation of time-dependent ROC curves for longitudinal marker data. Biostatistics. 2004;5(4):515–32.
13. Foucher Y, Danger R. Time dependent ROC curves for the estimation of true prognostic capacity of microarray data. Stat Appl Genet Mol Biol. 2012;11(6):Article 1.
14. Zhu X, Gou X, Zhou M. Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study. Front Oncol. 2019;9:846 (undefined).
15. Steyerberg E, Vickers A. Decision curve analysis: a discussion. Med Decis Mak. 2008;28(1):146–9.
16. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74.
17. Li J, Fine J. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Stat Med. 2004;23(16):2537–50.
18. Obuchowski NA, Zhou XH. Prospective studies of diagnostic test accuracy when disease prevalence is low. Biostatistics. 2002;3(4):477–92.
19. Katayama Y, Oshima T, Sakamaki K, Aoyama T, Sato T, Murako K, Shiozawa M, Yoshikawa T, Nino Y, Imada T, et al. Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy. In vivo. 2017;31(4):565–71.
20. Hofland J, van Weerden WM, Steenbergen J, Dits NF, Jenster G, de Jong FH. Activin a stimulates AKR1C3 expression and growth in human prostate cancer. Endocrinology. 2012;153(12):5726–34.
21. Chen ZL, Qin L, Peng XB, Hu Y, Li B. INHBA gene silencing inhibits gastric cancer cell migration and invasion by impeding activation of the TGF-β signaling pathway. J Cell Physiol. 2019;234(10):18065–74.
22. Lascorz J, Forsti A, Chen B, Buch S, Steinke V, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Gorgens H, et al. Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. Carcinogenesis. 2010;31(9):1612–9.
23. Seder CW, Hartojo W, Lin L, Silvers AS, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia. 2009;11(4):388–96.
24. Xie F, Jin K, Shao L, Fan Y, Tu L, Li Y, Yang S, van Dam H, ten Dijke P, Wang H, et al. FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. Nat Commun. 2017;8: 15021.
25. Zhao Y, Yang L, He J, Yang H. STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma. Tumor Biol. 2017;39(7):1010428317711644.
26. Xiao Y, Peng H, Hong C, Chen Z, Deng X, Wang A, Yang F, Yang L, Chen C, Qin X. PDGF promotes the Warburg effect in pulmonary arterial smooth muscle cells via activation of the PI3K/AKT/mTOR/HIF-1alpha signaling pathway. Cell Physiol Biochem. 2017;42(4):1603–13.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
28. Hald A, Schneeweiss J, Kalsi V, Arya M. The dukes staging system: a cornerstone in the clinical management of colorectal cancer. Lancet Oncol. 2009;10(11):11128.
29. De Roock W, De Reyniet V, Normann N, Gardiello F, Teijpar S, KRAS, Braf, PiK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.
30. Nebbioso P, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marucci G, Ogino S, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011;9(suppl 5):S1–32 quiz S33.
31. Massecesi C, Norman A, Price T, Hill M, Ross P, Cunningham D. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer. 2000;36(16):2044–52.
32. Tez M, Tez S. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;248(1):141–2 author reply 142.
33. Kanemitsu Y, Kato T. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg. 2008;32(6):1097–107.
34. Takakura Y, Okajima M, Kanemitsu Y, Kuroda S, Egí H, Hinoi T, Tashiro H, Ohdan H. External validation of two nomograms for predicting patient survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2011;35(10):2275–82.
35. Reddy SK, Kattan MW, Yu C, Ceppa EP, de la Fuente SG, Fong Y, Clay BM, White RR. Evaluation of peri-operative chemotherapy using a prognostic nomogram for survival after resection of colorectal liver metastases. HPB (Oxford). 2009;11(7):592–9.
36. Fendler WP, Ilhan H, Paprottka PM, Jakobs TF, Heinemann V, Bartenstein P, Khalaf F, Ezziddin S, Hacker M, Haug AR. Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. Eur Radiol. 2015;25(9):2693–700.
37. Elias D, Faron M, Goere D, Dumont F, Honore C, Boige V, Malka D, Ducreux M. A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol. 2014;21(6):2052–8.
38. Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, Bonneterre JF, Bosset JF, Bujko K, Dionisio JI, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163–72.
39. van Gijn W, van Stiphout RG, van de Velde CJ, Valentini V, Lammering G, Gambacorta MA, Pahlman L, Bujko K, Lambin P. Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy. Ann Oncol. 2015;26(5):928–35.
40. Peng J, Ding Y, Tu S, Shi D, Sun L, Li X, Wu H, Cai S. Prognostic nomograms for predicting survival and distant metastases in locally advanced rectal cancers. PLoS One. 2014;9(8):e106344.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.